Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: A prospective multicenter study involving 2,441 patients

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 532-538

  Lortholary, Olivier ^a,b,c   Desnos Ollivier, Marie ^a,b   Sitbon, Karine ^a,b   Fontanet, Arnaud ^a   Bretagne, Stéphane ^a,b,d   Dromer, Françoise ^a,b   Bouges Michel, C ^e   Poilane, I ^f   Dunan, J ^g   Galeazzi, G ^h   Botterel, F ^d,l   Fauchet, N ⁱ   Forget, E ^j   Lawrence, C ^k   Bonnal, C ^l   Bouree, P ^l   Eloy, O ^m   David, M F ⁿ   Khassis, N ⁿ   Milhaila, L ⁿ   Chachaty, E ^o   Chochillon, C ^p   Paugam, A ^q   Baixench, M T ^q   Cornet, M ^r   Escande, M C ^s   Bougnoux, M E ^t   Sterckers, Y ^t   Challier, S ^t   Dannaoui, E ^u   Lavarde, V ^u   Datry, A ^v   Lmimouni, B ^v   Brun, S ^v   Fekkar, A ^v   Poirot, J L ^w   Lacroix, C ^x   Moissenet, D ^y   Develoux, M ^z   Bonacorsi, S ^aa   more..

^a INSTITUT PASTEUR   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e AVICENNE HOSPITAL   (France)

^f HÔPITAL JEAN VERDIER   (France)

^g HÔPITAL AMBROISE PARÉ   (France)

^h HÔPITAL LOUIS MOURIER   (France)

ⁱ Centre Intercommunal   (France)

^j BEAUJON HOSPITAL   (France)

^k RAYMOND POINCARÉ HOSPITAL   (France)

^l BICÊTRE HOSPITAL   (France)

^m CENTRE HOSPITALIER   (France)

ⁿ HÔPITAL PAUL BROUSSE   (France)

^o INSTITUT GUSTAVE ROUSSY   (France)

^p BICHAT HOSPITAL   (France)

^q Institut Gustave Roussy ^*  (France)

^r Hôpital Bichat ^*  (France)

^s INSTITUT CURIE   (France)

^t HÔPITAL NECKER ENFANTS MALADES   (France)

^u HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^v PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^w HÔPITAL SAINT ANTOINE   (France)

^x SAINT LOUIS HOSPITAL   (France)

^y SERVICE DE DERMATOLOGIE   (France)

^z HÔPITAL TENON   (France)

^aa HÔPITAL ROBERT DEBRÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; FLUCONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDEMIA; CHILD; CLINICAL TRIAL; DRUG EXPOSURE; FEMALE; FRANCE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEWBORN; NONHUMAN; PARASITE PREVALENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD;

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; CROSS INFECTION; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FLUCONAZOLE; FRANCE; HUMANS; MICROBIAL SENSITIVITY TESTS; PARIS; POPULATION SURVEILLANCE; PREVALENCE; PROSPECTIVE STUDIES; SPECIES SPECIFICITY;

EID: 78751679139     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01128-10     Document Type: Article

References (46)

1. Abi-Said, D., E. Anaissie, O. Uzun, I. Raad, H. Pinzcowski, and S. Vartivarian. 1997. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24:1122-1128.
2. Almirante, B., D. Rodriguez, B. J. Park, M. Cuenca-Estrella, A. M. Planes, M. Almela, J. Mensa, F. Sanchez, J. Ayats, M. Gimenez, P. Saballs, S. K. Fridkin, J. Morgan, J. L. Rodriguez-Tudela, D. W. Warnock, and A. Pahissa. 2005. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 43:1829-1835.
3. Bartizal, C., and F. C. Odds. 2003. Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:2100-2107.
4. Bassetti, M., F. Ansaldi, L. Nicolini, E. Malfatto, M. P. Molinari, M. Mussap, B. Rebesco, F. Bobbio Pallavicini, G. Icardi, and C. Viscoli. 2009. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J. Antimicrob. Chemother. 64:625-629.
5. Chen, S., M. Slavin, Q. Nguyen, D. Marriott, E. G. Playford, D. Ellis, and T. Sorrell. 2006. Active surveillance for candidemia, Australia. Emerg. Infect. Dis. 12:1508-1516.
6. Chow, J. K., Y. Golan, R. Ruthazer, A. W. Karchmer, Y. Carmeli, D. Lichtenberg, V. Chawla, J. Young, and S. Hadley. 2008. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin. Infect. Dis. 46:1206-1213.
7. Colombo, A. L., M. Nucci, B. J. Park, S. A. Nouer, B. Arthington-Skaggs, D. A. da Matta, D. Warnock, and J. Morgan. 2006. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J. Clin. Microbiol. 44:2816-2823.
8. Cornely, O. A., J. Maertens, D. J. Winston, J. Perfect, A. J. Ullmann, T. J. Walsh, D. Helfgott, J. Holowiecki, D. Stockelberg, Y. T. Goh, M. Petrini, C. Hardalo, R. Suresh, and D. Angulo-Gonzalez. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359.
9. Dannaoui, E., M. Desnos-Olllivier, D. Garcia-Hermoso, D. Raoux, D. Hoinard, F. Dromer, and O. Lortholary for the French Mycoses Study Group. 2010. Infections due to Candida spp. with reduced susceptibility to caspofungin in France, abstr. O346. Abstr. 20th Eur. Congr. Clin. Microbiol. Infect. Dis.
10. Desnos-Ollivier, M., S. Bretagne, D. Raoux, D. Hoinard, F. Dromer, and E. Dannaoui. 2008. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the EUCAST method. Antimicrob. Agents Chemother. 52:3092-3098.
11. European Committee on Antimicrobial Susceptibility Testing. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.
12. European Committee on Antimicrobial Susceptibility Testing. 2008. EUCAST technical note on fluconazole. Clin. Microbiol. Infect. 14:193-195.
13. Forrest, G. N., E. Weekes, and J. K. Johnson. 2008. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J. Infect. 56:126-129.
14. Garnacho-Montero, J., A. Diaz-Martin, E. Garcia-Cabrera, M. Ruiz Perez de Pipaon, C. Hernandez-Caballero, J. Aznar-Martin, J. M. Cisneros, and C. Ortiz-Leyba. 2010. Risk factors for fluconazole-resistant candidemia. Antimicrob. Agents Chemother. 54:3149-3154.
15. Hachem, R., H. Hanna, D. Kontoyiannis, Y. Jiang, and I. Raad. 2008. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112:2493-2499.
16. Hajjeh, R. A., A. N. Sofair, L. H. Harrison, G. M. Lyon, B. A. Arthington-Skaggs, S. A. Mirza, M. Phelan, J. Morgan, W. Lee-Yang, M. A. Ciblak, L. E. Benjamin, L. T. Sanza, S. Huie, S. F. Yeo, M. E. Brandt, and D. W. Warnock. 2004. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42:1519-1527.
17. Horn, D. L., D. Neofytos, E. J. Anaissie, J. A. Fishman, W. J. Steinbach, A. J. Olyaei, K. A. Marr, M. A. Pfaller, C. H. Chang, and K. M. Webster. 2009. Epidemiology and outcomes of candidemia in 2019 patients: data from the Prospective Antifungal Therapy Alliance Registry. Clin. Infect. Dis. 48:1695-1703.
18. Katiyar, S., M. Pfaller, and T. Edlind. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894.
19. Lee, I., N. O. Fishman, T. E. Zaoutis, K. H. Morales, M. G. Weiner, M. Synnestvedt, I. Nachamkin, and E. Lautenbach. 2009. Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch. Intern. Med. 169:379-383.
20. Leroy, O., J. P. Gangneux, P. Montravers, J. P. Mira, F. Gouin, J. P. Sollet, J. Carlet, J. Reynes, M. Rosenheim, B. Regnier, and O. Lortholary. 2009. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit. Care Med. 37:1612-1618.
21. Lin, M. Y., Y. Carmeli, J. Zumsteg, E. L. Flores, J. Tolentino, P. Sreeramoju, and S. G. Weber. 2005. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob. Agents Chemother. 49:4555-4560.
22. Maertens, J., O. Marchetti, R. Herbrecht, O. A. Cornely, U. Fluckiger, P. Frere, B. Gachot, W. J. Heinz, C. Lass-Florl, P. Ribaud, A. Thiebaut, and C. Cordonnier. 26 July 2010, posting date. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant. [Epub ahead of print.]
23. Marchetti, O., J. Bille, U. Fluckiger, P. Eggimann, C. Ruef, J. Garbino, T. Calandra, M. P. Glauser, M. G. Tauber, and D. Pittet. 2004. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin. Infect. Dis. 38:311-320.
24. Marr, K. A., K. Seidel, T. C. White, and R. A. Bowden. 2000. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 181:309-316.
25. Morgan, J. 2005. Global trends in candidemia: review of reports from 1995-2005. Curr. Infect. Dis. Rep. 7:429-439.
26. Oxman, D. A., J. K. Chow, G. Frendl, S. Hadley, S. Hershkovitz, P. Ireland, L. A. McDermott, K. Tsai, F. M. Marty, D. P. Kontoyiannis, and Y. Golan. 2010. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J. Antimicrob. Chemother. 65:1460-1465.
27. Pappas, P. G., C. A. Kauffman, D. Andes, D. K. Benjamin, Jr., T. F. Calandra, J. E. Edwards, Jr., S. G. Filler, J. F. Fisher, B. J. Kullberg, L. Ostrosky-Zeichner, A. C. Reboli, J. H. Rex, T. J. Walsh, and J. D. Sobel. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
28. Pappas, P. G., J. H. Rex, J. D. Sobel, S. G. Filler, W. E. Dismukes, T. J. Walsh, and J. E. Edwards. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189.
29. Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
30. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
31. Pfaller, M. A., D. J. Diekema, M. G. Rinaldi, R. Barnes, B. Hu, A. V. Veselov, N. Tiraboschi, E. Nagy, and D. L. Gibbs. 2005. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J. Clin. Microbiol. 43:5848-5859.
32. Pfaller, M. A., S. A. Messer, L. Boyken, R. J. Hollis, C. Rice, S. Tendolkar, and D. J. Diekema. 2004. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis. 48:201-205.
33. Playford, E. G., D. Marriott, Q. Nguyen, S. Chen, D. Ellis, M. Slavin, and T. C. Sorrell. 2008. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit. Care Med. 36:2034-2039.
34. Senn, L., P. Eggimann, R. Ksontini, A. Pascual, N. Demartines, J. Bille, T. Calandra, and O. Marchetti. 2009. Caspofungin for prevention of intraabdominal candidiasis in high-risk surgical patients. Intensive Care Med. 35:903-908.
35. Shorr, A. F., K. Chung, W. L. Jackson, P. E. Waterman, and M. H. Kollef. 2005. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit. Care Med. 33:1928-1935.
36. Shorr, A. F., D. R. Lazarus, J. H. Sherner, W. L. Jackson, M. Morrel, V. J. Fraser, and M. H. Kollef. 2007. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit. Care Med. 35:1077-1083.
37. Sipsas, N. V., R. E. Lewis, J. Tarrand, R. Hachem, K. V. Rolston, I. I. Raad, and D. P. Kontoyiannis. 2009. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115:4745-4752.
38. Slavin, M. A., T. C. Sorrell, D. Marriott, K. A. Thursky, Q. Nguyen, D. H. Ellis, C. O. Morrissey, and S. C. Chen. 2010. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J. Antimicrob. Chemother. 65:1042-1051.
39. Timsit, J., H. Dupont, J. Stahl, A. Tabah, O. Lortholary, C. Martin, A. Francais, B. Guidet, and E. Azoulay. 2009. Use of anitfungal therapy in ICU: a prevalent cohort study in 169 ICUs, abstr. M-1033/523. Abstr. 49th Intersci. Conf. Antimicrob. Chemother. American Society for Microbiology, Washington, DC.
40. Tortorano, A. M., J. Peman, H. Bernhardt, L. Klingspor, C. C. Kibbler, O. Faure, E. Biraghi, E. Canton, K. Zimmermann, S. Seaton, and R. Grillot. 2004. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur. J. Clin. Microbiol. Infect. Dis. 23:317-322.
41. Trick, W. E., S. K. Fridkin, J. R. Edwards, R. A. Hajjeh, and R. P. Gaynes. 2002. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 35: 627-630.
42. Trofa, D., A. Gacser, and J. D. Nosanchuk. 2008. Candida parapsilosis, an emerging fungal pathogen. Clin. Microbiol. Rev. 21:606-625.
43. Ullmann, A. J., J. H. Lipton, D. H. Vesole, P. Chandrasekar, A. Langston, S. R. Tarantolo, H. Greinix, W. Morais de Azevedo, V. Reddy, N. Boparai, L. Pedicone, H. Patino, and S. Durrant. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347.
44. Vincent, J. L., J. Rello, J. Marshall, E. Silva, A. Anzueto, C. D. Martin, R. Moreno, J. Lipman, C. Gomersall, Y. Sakr, and K. Reinhart. 2009. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323-2329.
45. Viscoli, C., C. Girmenia, A. Marinus, L. Collette, P. Martino, B. Vandercam, C. Doyen, B. Lebeau, D. Spence, V. Krcmery, B. De Pauw, and F. Meunier. 1999. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis. 28:1071-1079.
46. Wingard, J. R., W. G. Merz, M. G. Rinaldi, T. R. Johnson, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 18:1274.